T-EDTA
Nantwich
About T-EDTA
T-EDTA Limited was established to develop anti-biofilm technologies and infection control products. Anti-biofilm is used in advanced wound care products using the anti-biofilm agents tri sodium/tetra sodium EDTA (‘t-EDTA’). A biofilm is a group of microorganisms in which cells stick to each other and often adhere to a surface, such as wound. As such, they represent a major risk of woundsite infection. EDTA is a chemical which can inhibit the development of such biofilms. Biofilms are a major problem for human infections and medical device related infections due to their becoming resistant to antibiotics, with the result being wounds that are slow to heal, or not healing/remaining open. The patented tri and tetrasodium EDTA (‘T-EDTA’) can be used to prevent and control infection in three specific areas; advanced wound care, catheters and consumer wellness (Skin/foot fungal infections).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Last round: Series Unknown (Apr 2017)
Industries & Categories
Biotechnology, Health Care, Manufacturing
Canonical: https://fsome.com/organization/t-edta-2663817 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.